Kaplan-Meier estimates of the probability of survival in patients with high CFDNA levels (≥ 22,000 GE/ml, dotted line) vs. those with low CFDNA levels (< 22,000 GE/ml, full line) in Training Set (A). This cutoff was validated in a separate cohort of patients, Validation Set (B). Two-sided log rank test provided a significant p-value < 0.001.